Gene editing

Cancer cells
#Acute Myeloid Leukaemia #Cancer research #Cell and gene therapy #Clinical trials #Gene editing

First AML patient successfully transplanted with investigational drug 

Vor Bio, a clinical-stage cell and genome engineering company, has announced initial clinical data from VBP101, its Phase I/IIa multicentre, open-label, first-in-human study of tremtelectogene empogeditemcel or “trem-cel” (formerly VOR33) in patients with acute myeloid leukaemia (AML).   The data observed from the first treated patient support the… Read More

#Cancer Research #News

CRISPR gene editing
#Cell and gene therapy #CRISPR #DNA #Gene editing #Genetics / genomics

Delivering on the promise of gene editing

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced… Read More

#Exclusive Content

#Gene editing #Genetics / genomics #Japan #Muscular dystrophy #RNA

RNA interference method could treat muscular dystrophy

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy.  Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests itself in the form of a severe… Read More

#Editor's Choice #News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

CRISPR gene editing
#CRISPR #CRISPR screening #ELRIG #Events #Gene editing #Genetics / genomics

ELRIG meeting will focus on gene engineering in drug discovery

The fifth CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held face to face In Oxford on February 7-8, 2023.  The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular… Read More

#Editor's Choice #News

#Cell engineering #CRISPR #Gene editing #Target discovery #Target identification #Target validation

Reveal the best drug targets with Engineered Cell Libraries

CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your… Read More

Webinar date:
Brought to you by Synthego
#Webinars

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies - precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might argue that this all started… Read More

#Exclusive Content #Opinion #Trends & Analysis

Stomach cancer cells
#ATR inhibitors #Cancer #Cancer research #Cancer Research UK #CRISPR #Drug resistance #Gene editing #Genetic study #Stomach cancer #The Institute of Cancer Research

Study reveals how stomach cancers develop drug resistance

Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance.  The findings could pave the way for… Read More

#Cancer Research #News

#Collaboration #CRISPR #CRISPR-Cas9 #Cystic fibrosis #Finance #Gene editing #Liver disease #Neuropsychiatric disorders #Oncology #RNA

This week in drug discovery (10-14 October)

News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry.  Partnerships… Read More

#News

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #DNA #Gene editing #Spherical nucleic acid

Gene editing platform could shape future application of CRISPR-based therapeutics

A team of researchers at Northwestern University in the US has devised a new platform for gene editing that could inform the future application of CRISPR-based therapeutics. Using chemical design and synthesis, the team brought together the Nobel-prize winning technology with therapeutic technology born in their own lab to overcome… Read More

#News

#British Heart Foundation (BHF) #CRISPR #Gene editing #Heart disease #University of Oxford

International researchers win £30m for work in treating heart conditions  

An international team of researchers has won £30 million for its work in developing a potential cure for inherited heart muscle conditions in young people.  CureHeart was selected as the winner of the British Heart Foundation’s (BHF) Big Beat Challenge, which grants a £30 million non-commercial grant… Read More

#News

CRISPR gene editing
#3D modelling #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Screening

CRISPR screening in the third dimension 

Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.  While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the functional contribution of the mutated… Read More

#Editor's Choice #Exclusive Content #News

#Biotherapeutics #Cell therapy #Gene editing #Immunotherapy #T-Cells

Atara Biotherapeutics’ plans to tackle MS with Epstein-Barr Virus

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#CRISPR #Drug development #Drug discovery #Gene editing #R&D

Benchling launch cloud solution at virtual event  

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More

#News

#CRISPR #Drug discovery #Funding #Gene editing #HIV #Research

NIH invests $53 million in HIV cure research  

The National Institutes of Health (NIH) has awarded approximately $53 million in annual funding over the next five years to ten research organisations in a continued effort to find a cure for HIV.   The new awards for the Martin Delaney Collaboratories for HIV Cure Research programme expand the initiative’s 2016 renewal from six institutions to ten. Read More

#Business & Investment #News

#Clinical trials #Gene editing #Gene mutation #Gene therapy #Genetics / genomics #Research

Exploring gene-based medicine’s true potential

Listen to this article on the DDW Podcast: By Christopher Doyle, PhD, Director, IBC Services at WCG The Covid-19 pandemic spawned a flurry of research that culminated in the development of several vaccines that express viral proteins from recombinant or synthetic genetic material. The success of these new vaccines thrust the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News